RxDoctor Payments Data

Robert Belknap, MD

Adult Medicine · Mill Valley, CANPI 1336217306

Payments from drug & device makers

$522in general payments, 2019–2025

Across 13 payments — averaging $40.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$205
  • Abbott$144
  • Novo Nordisk$65
  • Johnson & Johnson$32
  • Kowa Pharmaceuticals America, Inc.$24
  • Genentech USA, Inc.$15
  • plus $37 from 3 others

What the payments were for

  • Food & beverage$45788%
  • Education$6512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$522 in reported general payments places this provider in the 65th percentile of 221 adult medicine providers in California.

See all adult medicine providers in California

Medicare billing

Part B allowed, 2024
$85,507
Medicare patients
171
Services billed
730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab76$59,881
EliquisApixaban46$49,721
OzempicSemaglutide27$35,183
RybelsusSemaglutide33$31,309
MyrbetriqMirabegron36$28,760
TradjentaLinagliptin18$24,643
JanuviaSitagliptin Phosphate12$19,615
JardianceEmpagliflozin11$18,866
LivaloPitavastatin Calcium17$11,117
Tresiba Flextouch U-200Insulin Degludec16$10,706
SynthroidLevothyroxine Sodium56$4,118
DayvigoLemborexant11$3,614
Celecoxib55$2,895
PaxlovidNirmatrelvir/Ritonavir33$2,858
Buprenorphine12$2,850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$65$66,49260 claims
PfizerEliquis, Paxlovid$14$52,57979 claims
Boehringer IngelheimTradjenta, Jardiance$12$43,50929 claims
Kowa Pharmaceuticals America, Inc.Livalo$24$11,11717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 221 adult medicine providers in California.

Other adult medicine in Mill Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →